VOLUME 9 (2018)
View Archive »
About The Cover
The cover for issue 77 of Oncotarget features Figure 2, "In mouse PCTs, deletion of hs3b-4 does not affect the pattern of chromosomal translocations but significantly increases targeting of Sμ for T(12;15)," by
Kovalchuk, et al.
Table of Contents
News
|
| An HTS FP assay able to selectively identify STAT3DBD inhibitors |
|
https://doi.org/10.18632/oncotarget.26155
|
| 34451-34452 |
|
| Can drug repurposing stop “chase and run†between aldehydes and reactive sulfur species in anticancer therapy |
|
https://doi.org/10.18632/oncotarget.26170
|
| 34453-34454 |
|
| Unfolding the roles of resveratrol in p53 regulation |
|
https://doi.org/10.18632/oncotarget.26185
|
| 34455-34456 |
Editorial
|
| A new BRaf inhibitor combo for advanced melanoma |
|
https://doi.org/10.18632/oncotarget.26171
|
| 34457-34458 |
Research Papers
|
| Characterization of murine CEACAM1 <i>in vivo</i> reveals low expression on CD8<sup>+</sup> T cells and no tumor growth modulating activity by antiCEACAM1 mAb CC1 |
|
https://doi.org/10.18632/oncotarget.26108
|
| 34459-34470 |
|
| The double stranded RNA analog polyIC elicits both robust IFNλ production and oncolytic activity in human gastrointestinal cancer cells |
|
https://doi.org/10.18632/oncotarget.26121
|
| 34471-34484 |
|
| Abdominal obesity and prostate cancer risk: epidemiological evidence from the EPICAP study |
|
https://doi.org/10.18632/oncotarget.26128
|
| 34485-34494 |
|
| Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formation |
|
https://doi.org/10.18632/oncotarget.26130
|
| 34495-34505 |
|
| Characteristic analysis of TCR βchain CDR3 repertoire for preand postliver transplantation |
|
https://doi.org/10.18632/oncotarget.26138
|
| 34506-34519 |
|
| Neutrophiltolymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study |
|
https://doi.org/10.18632/oncotarget.26145
|
| 34520-34527 |
|
| 3’<i>Igh</i> enhancers hs3b/hs4 are dispensable for <i>Myc</i> deregulation in mouse plasmacytomas with T12;15 translocations |
|
https://doi.org/10.18632/oncotarget.26160
|
| 34528-34542 |
|
| Genetically coating oncolytic herpes simplex virus with CD47 allows efficient systemic delivery and prolongs virus persistence at tumor site |
|
https://doi.org/10.18632/oncotarget.26167
|
| 34543-34553 |
|
| Mutant TP53 modulates metastasis of triple negative breast cancer through adenosine A2b receptor signaling |
|
https://doi.org/10.18632/oncotarget.26177
|
| 34554-34566 |
|
| XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies |
|
https://doi.org/10.18632/oncotarget.26179
|
| 34567-34581 |
|
| Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma |
|
https://doi.org/10.18632/oncotarget.26180
|
| 34582-34594 |
|
| Upregulation of heme oxygenase1 expression and inhibition of diseaseassociated features by cannabidiol in vascular smooth muscle cells |
|
https://doi.org/10.18632/oncotarget.26191
|
| 34595-34616 |
|
| Surrogate endpoints in advanced sarcoma trials: a metaanalysis |
|
https://doi.org/10.18632/oncotarget.26166
|
| 34617-34627 |
Reviews
|
| The clinical relevance of progestogens in hormonal contraception: Present status and future developments |
|
https://doi.org/10.18632/oncotarget.26015
|
| 34628-34638 |
Corrections
|
| Correction: Everolimus EVE and exemestane EXE in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study |
|
https://doi.org/10.18632/oncotarget.26213
|
| 34639-34640 |
|
| Correction: Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using <sup>64</sup>Cuplerixafor PET |
|
https://doi.org/10.18632/oncotarget.26214
|
| 34641-34641 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß
